Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders

News
2023
2022
Archive

January 18, 2023

Dianthus Therapeutics Strengthens Leadership Team with Appointment of Susan Kalled, Ph.D., as Chief Scientific Officer
January 12, 2023

California Department of Health Care Services Awards Contract to Pear Therapeutics to Support the Recovery Incentives Program
January 12, 2023

Scientist.com Announces Launch of Research Marketplace for BIAL
January 10, 2023

Pear Therapeutics and Coeus Healthcare Partner to Combat the Addiction Crisis with Prescription Digital Therapeutics
January 9, 2023

CinCor Pharma to be Acquired by AstraZeneca
January 9, 2023

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
January 9, 2023

Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
January 9, 2023

IDEAYA Announces IND Clearance by U.S. FDA enabling Phase 1 Initiation for First-in-Class PARG Development Candidate IDE161
January 6, 2023

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer
January 5, 2023

Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs

© 2023 5AM Venture Management LLC